Please login to the form below

Not currently logged in
Email:
Password:

Juniper Pharmaceuticals adds to board of directors

Mary Ann Gray joins as audit committee chair

Juniper Mary Ann GrayBoston-based Juniper Pharmaceuticals has elected Mary Ann Gray to its board of directors and appointed her as its audit committee chair.

Dr Gray has over 20 years of biotechnology and biopharmaceutical experience and is the owner and president of Gray Strategic Advisors as well as serving on the boards of Acadia Pharmaceuticals, Senomyx Inc. and TetraLogic Pharmaceuticals.

Prior to its acquisition by Shire earlier this year, Dr Gray was lead director at Dyax Corporation and has also held senior roles at the Federated Kaufmann Fund, GTC Biotherapeutics and Schering-Plough.

Jim Geraghty, Juniper's chairman, said: “Mary Ann is a highly qualified corporate director and experienced audit committee chair, and we are very pleased to have her join Juniper's board.

“Her unique blend of Wall Street, financial, and scientific experience will be a tremendous asset as Juniper continues to advance its clinical programs to drive long-term shareholder value.”

Gray succeeds Donald Hunter, who tendered his resignation from the board last year.

Geraghty added: “We deeply appreciate Don Hunter's contributions during his tenure on Juniper's board, and his willingness to provide continuity in his role as audit committee chair during our extensive search for the right person to succeed him.” 

6th April 2016

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
infill healthcare communication

infill is a dynamic and innovative, international healthcare agency with >25 years' experience in delivering healthcare communication, medical education and...

Latest intelligence

eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...
What is changing in cardiovascular disease care?
Paul Midgley, of Wilmington Healthcare, explores the NHS Long-term Plan’s strategy for tackling cardiovascular disease and what it means for pharma...

Infographics